Surveillance of travel-associated diseases at two referral centres in Marseille, France: a 12-year survey

Griffiths, Karolina; Savini, Hélène; Brouqui, Philippe; Simon, Fabrice; Parola, Philippe

doi:10.1093/jtm/tay007

Cited by 15 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth stressing that Maldivian public health authorities apparently have meticulous record-keeping and efficient surveillance systems. Local epidemiological data assist in the timely adaptation of travel recommendations and the prompt detection and management of viremic cases imported into places at risk of local spread [29]. Key concepts in the control of arboviral diseases threat include pre-travel targeted advice, early detection of sentinel cases, outbreak alert leading to prompt responses, and post-travel multi-disciplinary management of cases.…”

Section: Discussionmentioning

confidence: 99%

Chikungunya resurgence in the Maldives and risk for importation via tourists to Europe in 2019–2020: A GeoSentinel case series

Dudouet

Larsen

Díaz‐Menéndez

et al. 2020

Travel Medicine and Infectious Disease

Self Cite

View full text Add to dashboard Cite

Background: Chikungunya virus (CHIKV) is an arthropod-borne virus mainly transmitted in tropical areas by Aedes spp. mosquitoes. It has been responsible for small-to-large outbreaks in temperate areas including southern Europe and North America. Past outbreaks in 2006 on the islands of Maldives, as well as on other islands in the Indian Ocean and in Southeast Asia, demonstrated for the first time the capacity of CHIKV to disseminate through travel and transcontinental commerce, and revealed the major socioeconomic impact of CHIKV epidemics. Recently, CHIKV has been circulating in highly touristic areas including the Maldives, where 1736 cases were notified by the Health Protection Agency during 2019. Case series: Among EuroTravNet/GeoSentinel patient records, eight CHIKV-confirmed cases imported the Maldives to France, Germany, Denmark, Italy and Spain were identified between February 2019 and February 2020; exceeding the total number of CHIKV infections travel-acquired in Maldives reported to this surveillance network during the previous 10 years. Conclusions: The prevention and control of CHIKV introduction into naïve areas colonised by competent vectors is crucial. CHIKV outbreaks must be detected and reported in a timely manner. This must lead to adapted health information for international travellers and to prompt management of suspected imported cases. Conversely, travellers make for excellent sentinels and increased reports of imported cases might reflect a change in the level of endemicity or even herald an outbreak. Feedback to the local health authorities and matching this with local epidemiological surveillance data may lead to health benefits for the local population.

show abstract

Section: Discussionmentioning

confidence: 99%

Chikungunya resurgence in the Maldives and risk for importation via tourists to Europe in 2019–2020: A GeoSentinel case series

Dudouet

Larsen

Díaz‐Menéndez

et al. 2020

Travel Medicine and Infectious Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, immunogenicity and safety data up to the age of 45 are available [69]. EMA has endorsed the age range from 9 to 45, but FDA has restricted the use of Dengvaxia to the age range of 9 to 16 [27,70,71].…”

Section: Indicated Age Range For Cyd-tdv In Travelersmentioning

confidence: 99%

The first licensed dengue vaccine: can it be used in travelers?

Wilder‐Smith

2019

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review: The first dengue vaccine (Dengvaxia®) was endorsed by the European Medicine Agency and the US Food and Drug Administration. Given the excess risk of severe dengue in seronegative vaccinees, use is restricted to seropositive individuals. Dengvaxia confers high protection against severe dengue in seropositive vaccinees. Recent findings: With increasing global travel, the probability of travelers being seropositive increases. Such seropositive travelers may be at increased risk of severe dengue as a result of a second dengue infection during repeat travel. Nevertheless, the use of Dengvaxia in travelers requires a careful analysis of all the factors. Seropositive travelers only present a minority of all travelers. A validated rapid diagnostic test to screen for dengue serostatus is not yet available. Such a test should be highly specific to avoid inadvertent vaccination of seronegative individuals. The 3-dose regimen precludes the use in most travelers who tend to present at travel clinics less than 6 weeks prior to departure. Furthermore, questions about potential sub-optimal immunogenicity in seropositives in non-endemic settings, and the need and timing of boosters remain unanswered. Conclusions: Although there could potentially be substantial protection against severe dengue in seropositive travelers, Dengvaxia is far from an ideal travel vaccine.

show abstract

“…2 Infected travelers can introduce dengue into nonendemic areas and contribute to its global spread. [3][4][5][6][7][8][9][10][11] With climate change-associated alterations in the geographic distribution of Aedes mosquitoes, 12 the risk of dengue introduction into Europe and North America has become a reality, as exemplified by the 2012 dengue outbreak in Madeira, Portugal, 6 although the overall risk of establishment of dengue in Europe was modeled to be low. 13 Large mass gathering events in dengue-endemic countries, such as the 2014 Fédération Internationale de Football Association World Cup and the Carnival in Brazil, now receive international attention for posing a potential health threat to travelers and to populations in non-endemic countries.…”

Section: Introductionmentioning

confidence: 99%

A Prospective Study on the Impact and Out-of-Pocket Costs of Dengue Illness in International Travelers

Tozan

Headley

Sewe

et al. 2019

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Although the costs of dengue illness to patients and households have been extensively studied in endemic populations, international travelers have not been the focus of costing studies. As globalization and human travel activities intensify, travelers are increasingly at risk for emerging and reemerging infectious diseases, such as dengue. This exploratory study aims to investigate the impact and out-of-pocket costs of dengue illness among travelers. We conducted a prospective study in adult travelers with laboratory-confirmed dengue and recruited patients at travel medicine clinics in eight different countries from December 2013 to December 2015. Using a structured questionnaire, we collected information on patients and their health-care utilization and out-of-pocket expenditures, as well as income and other financial losses they incurred because of dengue illness. A total of 90 patients participated in the study, most of whom traveled for tourism (74%) and visited countries in Asia (82%). Although 22% reported hospitalization and 32% receiving ambulatory care while traveling, these percentages were higher at 39% and 71%, respectively, after returning home. The out-of-pocket direct and indirect costs of dengue illness were US$421 (SD 744) and US$571 (SD 1,913) per episode, respectively, averaging to a total out-of-pocket cost of US$992 (SD 2,052) per episode. The study findings suggest that international travelers incur important direct and indirect costs because of dengue-related illness. This study is the first to date to investigate the impact and out-of-pocket costs of travel-related dengue illness from the patient's perspective and paves the way for future economic burden studies in this population.

show abstract

Surveillance of travel-associated diseases at two referral centres in Marseille, France: a 12-year survey

Cited by 15 publications

References 30 publications

Chikungunya resurgence in the Maldives and risk for importation via tourists to Europe in 2019–2020: A GeoSentinel case series

Chikungunya resurgence in the Maldives and risk for importation via tourists to Europe in 2019–2020: A GeoSentinel case series

The first licensed dengue vaccine: can it be used in travelers?

A Prospective Study on the Impact and Out-of-Pocket Costs of Dengue Illness in International Travelers

Contact Info

Product

Resources

About